Greater Flexibility and Improved QOL Represent Key Potential Benefits With Liquid TKI Formulations: With Jonathan Trent, MD, PhD
Share
Subscribe
Jonathan Trent, MD, PhD, discusses the clinically available TKIs for GIST and the potential benefits of liquid TKI formulations for this disease.
In today’s episode, we spoke with Jonathan Trent, MD, PhD, a professor in the Department of Medicine in the Division of Medical Oncology, associate director of Clinical Research, and the director of the Sarcoma Medical Research Program at the University of Miami Miller School of Medicine in Florida.
In our exclusive interview, Dr Trent discussed currently approved TKIs for patients with gastrointestinal stromal tumor (GIST), including imatinib (Gleevec), sunitinib (Sutent), regorafenib (Stivarga), and ripretinib (Qinlock). Trent dove into how these TKIs have improved outcomes for patients and touched on common adverse effects seen with these therapies, as well as how to manage these toxicities and maintain treatment adherence among patients. He also looked to liquid formulations of TKIs that are in development and the benefits they would bring to GIST management.